ERYTECH announces enrollment of first patient in Phase II study of eryaspase in pancreatic cancer Post author:admERY Post published:July 28, 2014 Post category:Newsroom ERYTECH announces the enrollment of the first patient in its Phase II study with eryaspase in second line treatment of patients affected by pancreatic cancer. You Might Also Like ERYTECH to present at upcoming investor conferences May 20, 2013 ERYTECH to Present Two Posters at AACR March 17, 2016 ERYTECH to Participate in the Citi 16th Annual BioPharma Conference August 30, 2021